The obesity epidemic in America is causing chronic conditions like type 2 diabetes, heart disease, and hypertension to rise at an alarming rate, putting significant strain on healthcare systems. While GLP-1 medications have shown impressive clinical results in treating obesity, in order for them to be effective, they must be combined with lifestyle changes.
Noom's 2024 retrospective study on its GLP-1 Companion program highlights the benefits of this integrated approach. The findings were life-changing:
Noom’s GLP-1 Care Gap white paper delves into the health and cost risks of the GLP-1 care gap, and explores how Noom’s programs enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications. Personalized support and comprehensive strategies can assist members in adopting healthier habits, achieving weight loss goals, and improve health outcomes, easing the strain on health systems and offering substantial cost benefits for organizations.
Download the white paper now and explore Noom’s GLP-1 Companion program for better health outcomes and cost savings.
By requesting this resource you agree to our terms of use. All data is protected by our Privacy Notice.
By submitting this form, you are confirming you are an adult of 18 years or older and you agree to Noom contacting you with marketing-related emails or by telephone. You may unsubscribe at any time. Noom websites and communications are subject to their Privacy Notice.